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Abstract During the last decade, the discovery of critical
tumor targets has boosted the design of targeted therapeutic
agents with monoclonal antibodies (mAbs) and tyrosine
kinase inhibitors (TKIs) receiving most of the attention.
Immuno-positron emission tomography (immuno-PET)
and TKI-PET, the in vivo tracking and quantification of
mAbs and TKIs biodistribution with PET, are exciting novel
options for better understanding of the in vivo behavior and
efficacy of these targeted drugs in individual patients and for
more efficient drug development. Very recently, current
good manufacturing practice compliant procedures for la-
beling of mAbs with positron emitters have been described,
as well as the preparation of some radiolabeled TKIs, while
the first proof of principle studies has been performed in
patients. In this review, technical developments in immuno-
PET and TKI-PET are described, and their clinical potential
is discussed. An overview is provided for the most appeal-
ing preclinical immuno-PET and TKI-PET studies, as well
as the first clinical achievements with these emerging
technologies.
Keywords Positronemissiontomography.Monoclonal
antibodies.Tyrosinekinaseinhibitors.Zirconium-89.
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Introduction
Recent advances in molecular and cellular biology have
resulted in the identification of critical molecular tumor
targets involved in proliferation, differentiation, cell death
and apoptosis, angiogenesis, immune recognition, invasion,
and metastasis. In addition, critical molecular targets have
been associated with cancer cell stemness. This knowledge
has boosted the rational design of cutting-edge pharmaceut-
icals, with monoclonal antibodies (mAbs) and tyrosine ki-
nase inhibitors (TKIs) forming the most rapidly expanding
categories. Presently, 12 mAbs, all being intact immunoglo-
bulins, and 12 TKIs have been approved by the US Food
and Drug Administration for the systemic treatment of can-
cer (Table 1). The total yearly sales of mAbs and TKIs is
estimated to be US $30 and $16 billion, respectively, mostly
spent for the treatment of cancer, while hundreds of new
mAb and TKI candidates are under clinical development by
biotech and pharmaceutical companies [1].
The tremendous development of new targeted drugs
might not only make optimism about future perspectives in
the treatment of cancer but also raises the question about
how to test all these drugs in an efficient way since in
current drug development practice, it would require numer-
ous clinical trials with large number of patients. Since just
10% of all anticancer drugs under clinical development will
eventually reach the market, it becomes increasingly impor-
tant to distinguish drugs with high potential from the ones
with low potential at an early stage. This needs better
understanding of the behavior and activity of those drugs
in the human body. Furthermore, the effectiveness of current
targeted therapies in oncology is limited, while their costs
are excessive and therefore challenging the health care
systems [2]. The questions are how to improve the efficacy
of drug development by which drugs can become less
G. A. M. S. van Dongen (*):A. J. Poot: D. J. Vugts
Department of Otolaryngology/Head and Neck Surgery,
VU University Medical Center,
De Boelelaan 1117,
1081 HVAmsterdam, The Netherlands
e-mail: gams.vandongen@vumc.nl
G. A. M. S. van Dongen: A. J. Poot:D. J. Vugts
Department of Nuclear Medicine and PET Research,
VU University Medical Center,
De Boelelaan 1117,
1081 HVAmsterdam, The Netherlands
Tumor Biol. (2012) 33:607–615
DOI 10.1007/s13277-012-0316-4Table 1 mAbs and TKIs approved by FDA
Generic name/year approved Trade name Target Cancer indication
Monoclonal antibodies FDA-approved
Rituximab, 1997 Rituxan CD20 Lymphoma
Trastuzumab, 1998 Herceptin HER2/neu Breast cancer
Gemtuzumab ozogamicin, 2000 Mylotarg CD33 Acute myeloid leukemia
Alemtuzumab, 2001 Campath-1H CD52 Chronic lymphatic leukemia
90Y-Ibritumumab tiuxetan, 2002 Zevalin CD20 Non-Hodgkin’s lymphoma
131I-Tositumomab, 2003 Bexxar CD20 Non-Hodgkin’s lymphoma
Bevacizumab, 2004 Avastin VEGF Colorectal cancer
Non-small cell lung cancer
Cetuximab, 2004 Erbitux EGFR Colorectal cancer
Head and neck cancer
Panitumumab, 2006 Vectibix EGFR Colorectal cancer
Ofatumumab, 2009 Arzerra CD20 Chronic lymphocytic leukemia
Ipilimumab, 2011 Yervoy CTLA-4 Melanoma
Brentuximab vedotin, 2011 Adcetris CD30 Anaplastic large cell lymphoma
Hodgkin lymphoma
Tyrosine kinase inhibitors FDA-approved
Imatinib, 2001 Gleevec PhC, cKIT, CD17 Chronic myeloid leukemia
Acute lymphoblastic leukemia
Myelo dysplastic disease
Myelo proliferative disease
Hyper eosinophilic syndrome
Chronic eosinophilic leukemia
Gastrointestinal stromal tumor
Gefitinib, 2003 Iressa EGFR Non-small cell lung cancer
Erlotinib, 2004 Tarceva EGFR Non-small cell lung cancer
Pancreatic cancer
Sorafenib, 2005 Nexavar VEGFR, PDGFR, RAF, Mek, Erk Hepato cellular carcinoma
Renal cell carcinoma
Dasatinib, 2006 Sprycel Src, ABL Chronic myeloid leukemia
Acute lymphoblastic leukemia
Sunitinib, 2006 Sutent FLT3, PDGFR, VEGFR, KIT Renal cell carcinoma
Gastrointestinal stromal tumor
Pancreatic cancer
Neuroendocrine tumors
Nilotinib, 2007 Tasigna BCR, ABL Chronic myeloid leukemia
Lapatinib, 2007 Tykerb EGFR, HER2 Breast cancer
Pazopanib, 2009 Votrient VEGFR 1,2,3 Renal cell carcinoma
Vandetanib, 2011 Caprelsa VEGFR, EGFR Thyroid cancer
Vemurafanib, 2011 Zelboraf BRAF Melanoma
Critozinib, 2011 Xalkori ALK, cMet Non-small cell lung cancer
CD cluster of differentiation, HER2/neu human epidermal growth factor receptor 2, VEGF vascular endothelial growth factor, EGFR epidermal
growth factor receptor, PhC Philadelphia chromosome, PDGFR platelet derived growth factor receptor, CTLA-4 cytotoxic T lymphocyte-associated
antigen 4, ALK anaplastic lymphoma kinase, cMET MNNG HOS transforming gene, Erk extracellular regulated kinase, FLT3 Fms-like tyrosine
kinase-3, BRAF serine/threonine-protein kinase B-Raf, BCR breakpoint cluster region gene, ABL v-abl abelson murine leukemia viral oncogene
homolog
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targeted drugs, and how to identify the patients with the
highest chance of benefit from treatment with these drugs?
In other words, when, how, and for whom should targeted
therapy be reserved? To answer these questions, better in-
sight in the in vivo behavior of therapeutic mAbs and TKIs
should be obtained, including their interaction with critical
disease targets, mechanism of action, and beneficial effects
in individual patients. For this, positron emission tomogra-
phy (PET) imaging with radiolabeled mAbs and TKIs is
particularly attractive and better qualified than single photon
emission computerized tomography (SPECT) imaging be-
cause it enables noninvasive whole body quantitative imag-
ing of these targeted drugs at superior spatial and temporal
resolution and sensitivity [3–6]. Whereas a typical PET
scanner can detect between 10e-11 M and 10e-12 M con-
centrations, the sensitivity of a typical SPECT scanner is
10–50 times less as many photons are lost by the absorption
of the SPECT collimators.
Monoclonal antibodies and TKIs for treatment of cancer
Currently, 12 mAbs have been approved by the FDA for the
treatment of cancer, all being intact mAbs [1]. Seven of the
mAbs have been approved for the treatment of hematolog-
ical malignancies, being rituximab, gemtuzumab ozogami-
cin, alemtuzumab, ibritumumab tiuxetan, tositumomab,
ofatumumab, and brentuximab vedotin. Five mAbs have
been approved for the therapy of solid tumors, and four of
them interfere with signal transduction pathways by target-
ing growth factors or the extracellular domain of their
receptors. Those mAbs comprise trastuzumab for the treat-
ment of metastatic breast cancer; cetuximab, bevacizumab,
and panitumumab for the treatment of colorectal cancer; and
cetuximab and bevacizumab for the treatment of head and
neck and non-small cell lung cancer. The fifth mAb, ipilu-
mumab, has an immunostimulatory effect via cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) directed against
melanoma. Most naked mAbs can also act via other effector
mechanisms than described above such as antibody-
dependent cellular cytotoxicity, complement-dependent cel-
lular cytotoxicity, or apoptosis induction. However, naked
mAbs have limited efficacy on their own and should pref-
erably be used in combination with chemo- or radiotherapy.
Alternatively, mAbs can be loaded with toxic payloads like
the radionuclides yttrium-90 or iodine-131 as in the case of
ibritumumab tiuxetan and tositumomab, respectively, or
with super toxic drugs as in the case of gemtuzumab ozo-
gamycin and brentuximab vedotin. The use of supertoxic
drugs is becoming increasingly popular, as illustrated by the
approval of gemtuzumab ozogamycin and brentuximab
vedotin (containing calicheamicin and auristatin as the
supertoxic drug, respectively) and the development of the
next generation anti-human epidermal growth factor
receptor 2 (HER2) therapeutics such as trastuzumab-DM1
(trastuzumab coupled to the supertoxic drug mertansine) [7].
However, for highly toxic conjugates, selective tumor
targeting is a must. Cross-reactivity of such supertoxic con-
jugates with normal tissues might result in unacceptable
toxicity, as was recently demonstrated for the anti-CD44v6
conjugate bivatuzumab-DM1 [8].
In contrast to mAbs, TKIs are capable of entering the
tumor cell where they compete for adenosine triphosphate
(ATP) binding sites of transmembrane receptor tyrosine
kinases, resulting in inhibition of signaling pathways. TKIs
like gefitinib, erlotinib, and vemurafanib are monospecific
and target just one tyrosine kinase, in this case epidermal
growth factor receptor (EGFR), while all other FDA-
approved TKIs are dual- or multispecific (see Table 1). Next
to reversible TKIs, more recently, also irreversible TKIs are
under investigation like the EGFR and HER2 inhibitors
afatinib and neratinib [9, 10]. In contrast to mAbs, TKIs
are fast kinetic molecules without immune-mediated effec-
tor functions and are not suitable for the delivery of toxic
payloads to tumors.
The potential of immuno-PET and TKI-PET
The ability of PET to quantitatively image the distribution of
radiolabeled drugs within the body makes this technique a
valuable tool at several stages of drug development and
application. From first-in-man clinical trials with new drugs,
it is important to learn about the ideal drug dosing for
optimal tumor targeting (e.g., saturation of receptors), the
uptake in critical normal organs to anticipate toxicity, and
the interpatient variation in pharmacokinetics and tumor
targeting. Drug imaging might provide this information in
an efficient and safe way with fewer patients treated at
suboptimal doses. Pretreatment imaging with the drug of
interest might also have added value for patient selection
because it can be used to assess target expression and drug
accumulation in all tumor lesions and normal tissues non-
invasively, quantitatively, and even over time. This infor-
mation might be particularly relevant for heterogeneous
tumor types or when targeted drugs are combined with other
treatment modalities like chemo- and radiotherapy, to find
routes of maximum synergism. Ideally, anatomical informa-
tion on tumor extension is obtained, like possibly with PET-
CT and PET-MRI, to enable the assessment of homogeneity
of tumor drug accumulation. Also, imaging during therapy
is attractive to show that tumor targeting is effective and
indeed results in antitumor effects as can be assessed by e.g.,
18F-fluorodeoxyglucose PET. If a targeted drug is not
effective in a particular patient, adaptive treatment can be
Tumor Biol. (2012) 33:607–615 609considered by dose escalation or by choosing targeted drugs
that inhibit compensatory pathways. Apart from applica-
tions in treatment planning, treatment monitoring, and re-
sponse monitoring, imaging with radiolabeled targeted
drugs like mAbs can also be used for diagnostic purposes
and for better understanding in vivo biology (“immunohis-
tochemistry in vivo”).
Radiolabeling of mAbs for immuno-PET
To enable visualization of a targeted drug with a PET
camera, the drug should be labeled with a positron emitter
in an inert way, i.e., that neither binding nor pharmacoki-
netic characteristics of the drug become altered. Moreover,
the physical half-life of the positron emitter should be com-
patible with the residence time of the targeted drug in the
body, which is typically several days for slow kinetic intact
mAbs and a couple of hours for the fast kinetic small
molecules like TKIs. Due to their large size of 150 kDa, it
is quite easy to radiolabel mAbs for PET imaging in an inert
way. Very recently, universal procedures were introduced
for radiolabeling of intact mAbs with the long-lived positron
emitters iodine-124 (
124I, t½0100.3 h) [11] and zirconium-
89 (
89Zr, t½078.4 h) [12], of which
89Zr is particularly
suitable in combination with internalizing mAbs. For radio-
labeling of mAb fragments, which are more rapidly cleared
from the body than intact mAbs, short-lived positron emitters
becameavailablelikegallium-68(t½01.13h),copper-64(t½0
12.7 h), yttrium-86 (t½014.7 h), and bromine-76 (t½016.2 h).
Of these, the short-lived positron emitter gallium-68 (
68Ga) is
of particular clinical interest because it can be obtained from a
commercially available long life-span
68Ge/
68Ga-generator
(half-life 271 days), making it continuously available even
for centers without a cyclotron and at reasonable costs. For
some comprehensive reviews on positron emitters for
immuno-PET, see references [13–15].
Due to the fact that most therapeutic mAbs are internal-
izing intact mAbs,
89Zr nowadays becomes most broadly
applied. To make this happen, crucial achievements have
been obtained in the production [12, 16, 17] and commercial
availability of
89Zr for clinical use [12], the development of
a chelate for facile and stable coupling of
89Zr to mAbs
[18–20], and the development of protocols for labeling of
mAbs with
89Zr in a current good manufacturing practice
(cGMP) compliant way [19]. In Europe, it takes 3–4 months
of preparation before a
89Zr-labeled mAb can be evaluated
in a clinical trial, including all the steps of setting up radio-
chemistry and quality controls in a cGMP compliant way,
performing productions for validation of procedures, and
taking regulatory hurdles.
During the past years, several preclinical and clinical
124I- and
89Zr-immuno-PET studies have been performed
with intact mAbs, for example, with mAbs U36 (anti-
CD44v6) [21], DN30 (anti-cMet) [22], G250 (anticarbonic
anhydrase IX) [23–25], L19-SIP (antifibronectin) [11],
R1507 (anti-IGF-1R) [26], J591 and 7E11 (antiprostate-
specific membrane antigen (PSMA)) [27, 28], TCR105
(anti-CD105) [29], cetuximab (anti-EGFR) [30, 31], inbri-
tumumab tiuxetan (anti-CD20) [32], rituximab (anti-CD20)
[33], bevacizumab (anti-vascular endothelial growth factor
(VEGF)) [34, 35], and trastuzumab (anti-HER2) [36–38].
Radiolabeling of TKIs for TKI-PET
In contrast to the radiolabeling of mAbs, radiolabeling of
small molecules (<1 kDa) like TKIs is much more challeng-
ing and requires a drug-specific labeling strategy. In many
cases, labeling with
11C( t½020 min) will appear possible,
while in some cases, the chemical structure of the drug will
allow labeling with
18F( t½0110 min). To increase chemical
flexibility, radiolabeled TKI analogs are also used for PET
imaging [5, 39]. However, to be sure that a PET tracer
exactly represents the TKI of interest and to avoid extra
regulatory hurdles, it is better to use labeling strategies that
end up with exactly the original TKI chemical structure in
which a cold carbon or fluorine atom has been substituted
by
11Co r
18F, respectively.
While mAbs are normally metabolically stable in the
blood circulation and therefore radioactivity uptake in
organs will represent mAb uptake, this can be different for
radiolabeled TKIs. In case of TKIs, radioactive metabolites
might be formed, which do not represent the biodistribution
of the original TKI. The arising deviations can be depending
on the position of the radioactive atom in the TKI. To this
end, it might be interesting to label a TKI at different
positions if possible and to select the most suitable candidate
tracer. Nevertheless, before starting clinical trials with radio-
labeled TKIs, the evaluation of their in vivo stability and the
identification of metabolites are crucial, especially to make
the quantification of TKI biodistribution possible.
Noninvasive in vivo quantification of TKIs in TKI-PET
studies requires tracer kinetic models that describe uptake,
retention, and clearance of the tracer in tissue. For this, the
input function, i.e., the time course of the tracer in arterial
plasma, should be known. Routinely, the time course of
radioactivity in the whole blood and plasma is measured
continuously using an online withdrawal and detection sys-
tem. However, plasma usually contains labeled metabolites.
The proper input function for the kinetic model is the
metabolite-corrected plasma curve, and therefore at set
times, additional discrete samples (usually seven during a
60-min scan) are collected to correct for labeled metabolites.
During the past years, procedures for radiolabeling of
several FDA-approved anticancer TKIs have been described,
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11C-imatinib [40],
11C-gefitinib[41–43],
18F-gefitinib
[44, 45],
18F-sunitinib [46],
11C-erlotinib [47],
18F-lapatinib
[48], and
11C-sorafenib [49]; however, only few of these tracers
have been evaluated in animal models and just one in a clinical
trial of which the results have not been published yet.
Experiences with immuno-PET
Preclinical immuno-PET has been used for different kinds
of applications. Many studies have been focusing on the
quantitative evaluation of mAbs for their capacity to target
tumors selectively and on the assessment of the expression
of critical tumor targets like CD20 [32, 33], CD105 [29],
CD44v6 [21], cMet [22], PSMA [27, 28], IGF-1R [26],
EGFR [30, 31], HER2 [36–38], and VEGF [34, 35]. In
several of these studies, immuno-PET was evaluated for its
suitability asscouting procedure prior toradioimmunotherapy
to predict biodistribution and dosimetry of the corresponding
therapeutic radioimmunoconjugates. For this purpose, the
diagnostic radioimmunoconjugate should show a similar bio-
distribution as the therapeutic radioimmunoconjugate [50]. It
was shown that
89Zr-ibritumumab tiuxetan is suitable for the
prediction of
90Y-ibritumumab tiuxetan biodistribution [32],
89Zr-cetuximab for
90Y-cetuximab and
177Lu-cetuximab bio-
distribution [30], and
124I-L19-SIP for
131I-L19-SIP biodistri-
bution [11].Inotherstudies,
89Zr-immuno-PETwasevaluated
for imaging and quantification of “therapeutic effect sensors”
[6]. These are proteins whose expression is modulated in
response to the functional inhibition of a drug target. For
example, HER2 and VEGF are known to be downregulated
uponHsp90inhibition,andtheirdownregulationcouldindeed
be visualized in vivo by the use of PETwith
89Zr-trastuzumab
[38] and
89Zr-bevacizumab [35], respectively. Therapeutic
response upon chemo-, hormone-, and radiotherapy was also
evaluatedinanother
89Zr-immuno-PETapproach.Ruggieroet
al. [28] used in their studies
89Zr-7E11, a novel mAb directed
against an intracellular epitope of PSMA. In vivo
89Zr-7E11
canonlybindtoPSMAincasedeadordyingcellsarepresent.
The authors showed that
89Zr-7E11 can be used to monitor
and quantify, with high specificity, tumor response upon ther-
apy in PSMA-positive prostate tumors. In another approach,
89Zr-immuno-PET appeared suitable for imaging of tumor
hypoxia. To this end,
89Zr-cG250 was used for detection of
the membrane protein CAIX, which is involved in pH
regulation and is upregulated in many tumors in case of
hypoxia [25].
The disadvantage of using intact mAbs for confirmation
of target expression with immuno-PET is their long resi-
dence time ranging from days to over weeks and the rela-
tively low tumor-to-nontumor ratios at early time points
after injection. In addition, the large size of a mAb molecule
on one hand limits its diffusion from the vasculature into
tumor, while on the other hand results in unspecific tumor
uptake due to an enhanced permeability and retention effect.
For this purpose, the use of mAb fragments or engineered
proteins like diabodies and nanobodies might be an option.
These fast kinetic antibody-based PET probes allow same-
Fig. 1 Immuno-PET images
with
89Zr-cmAb U36 of head
and neck cancer patient with a
tumor on the right side of the
soft palate and a lymph node
metastasis at the left side of the
neck (level III). Images were
obtained 72 h post injection.
a Coronal image of primary
tumor. b Coronal image of
lymph node metastasis in the
neck. c Sagittal image of
primary tumor. d Sagittal
image of lymph node metastasis
in the neck (from Börjesson
et al. [21])
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target expression, as recently described by the group of
Wu [51, 52].
Some recent landmark studies also illustrate the potential
of immuno-PET in clinical settings.
124I-immuno-PET was
evaluated for in vivo profiling of renal cancer. Divgi et al.
[24] used
124I-cG250 to predict the presence of clear-cell
renal carcinomas in 25 patients scheduled for surgical tumor
resection. It might be informative to identify those renal
cancer patients who have this aggressive type because of
treatment decisions. Of the 16 clear-cell patients, 15 were
identified accurately by immuno-PET, and all 9 nonclear-
cell renal masses were negative for the tracer. This study
illustrates how molecular imaging can contribute to person-
alized medicine.
The first clinical
89Zr-immuno-PET study ever was
reported in 2006 by Börjesson et al. [21]. This feasibility
study with 20 head and neck cancer patients showed that
89Zr-cmAb, directed against CD44v6, can be safely applied
in patients and that it is a promising tool for PET detection
of primary tumors as well as of metastases in the neck
(Fig. 1). In this study, biodistribution, radiation dose, and
quantification potential of immuno-PET were also assessed
[53]. PET quantification of blood-pool activity in the left
ventricle was in good agreement with sampled blood activ-
ity, except for heavy weight patients (>100 kg). The same
accounts for the uptake in tumor tissue, where a good
agreement was observed between PET-derived data and
biopsy data. This suggests that patients with high and low
mAb uptake can be differentiated, which might be important
for the selection of patients with the highest chance of
benefit from mAb therapy.
High quality images were obtained by Dijkers et al. [37]
in an immuno-PET study with
89Zr-trastuzumab in breast
cancer patients. In this feasibility study with 14 patients,
three different dose cohorts were evaluated: 10 or 50 mg for
trastuzumab-naïve patients and 10 mg for patients on
trastuzumab treatment. It was proven that the latter two
performed equally. Although this study was not aiming
for the comparison with conventional staging modalities
or for assessing specificity and sensitivity, lesions with
89Zr-trastuzumab uptake were generally in good agree-
ment with CT, MRI, and bone scans. PET images
showed a high spatial resolution and a good signal-to-
noise ratio, which resulted in an image quality unap-
proachable by previous
111In-trastuzumab SPECT scans.
Excellent visualization of mAb uptake in HER2-positive
lesions as well as in metastatic liver, lung, bone, and
even brain HER2-positive lesions was observed (Fig. 2).
89Zr-trastuzumab PET allowed the quantification of con-
jugate uptake in HER2-positive lesions, and it became
clear that for some patients with extensive tumor load, no
HER2 saturation occurred during trastuzumab therapy.
Fig. 2 Examples of
89Zr-trastuzumab uptake 5 days
p.i. in a patient with liver and
bone metastases (a) and two
patients with multiple bone
metastases (b, c). A number of
lesions have been specifically
indicated by the arrows
(from Dijkers et al. [36])
Fig. 3
11C-erlotinib micro-PET imaging of lung cancer xenografts.
Coronal micro-PET images of anesthetized athymic nude mice xeno-
grafted with A549 (a), NCI358 (b), and HCC827 (c) lung cancer cells
at the left shoulder. A549 and NCI358 cell lines are less sensitive to
erlotinib than HCC827, while the latter cell line harbors an inframe
deletion mutation in exon 19 of EGFR. White arrows tumors. It can be
concluded that the highest tumor uptake of
11C-erlotinib was found in
the most sensitive xenograft line HCC827. The hot spot in a (red
arrow) was found in all mice; however, it is not possible to show
it in all mice as the tumors are located in different planes. Liver
is seen with very high activity with spillover to the surrounding
area (arrowheads) (derived from Memon et al. [47])
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PET imaging might also contribute to better understanding
of TKI activity, although preclinical in vivo proof of concept
studies are scarce and thus far limited to
11C-gefitinib,
18F-
gefitinib,
11C-erlotinib, and
11C-sorafenib. The most appeal-
ing results have been obtained with erlotinib and gefitinib,
which compete with ATP for the ATP-binding site on the
EGFR, thereby preventing signal transduction leading to
proliferation. Erlotinib and gefitinib can induce dramatic
clinical responses but only in 4–10% of HNSCC patients
and 10–15% of non-small-cell lung cancer (NSCLC)
patients, when used as single agents [54]. Expression and
mutation status of the EGFR have been associated with
increased response [54]. It has been hypothesized that the
presence of sensitizing mutations might increase the binding
of the drug with its target. This might result in better drug
retention within the tumor as well as in a more efficient
inhibition of signaling through EGFR. However, for the
assessment of EGFR expression and mutation status, a
tumor biopsy has to be taken, which is not always possible
like in NSCLC. Even when a biopsy is available, it is
questionable whether this is sufficient to obtain a represen-
tative overview of the whole (often heterogeneous) tumor.
Moreover, it is possible that expression and mutation
status differ in primary tumor and metastatic lesions
and change during the course of disease, for example,
upon chemo- or radiotherapy. Taking this into account, it
might be that PET imaging with the radiolabeled EGFR
TKI itself gives a more comprehensive overview of
EGFR receptor status and the interaction of the drug
with this receptor. To test this possibility, Memon et al.
[47] evaluated the uptake of
11C-erlotinib in nude mice
bearing lung cancer xenograft lines with a different sen-
sitivity to erlotinib treatment and a different mutation
status. In mice carrying the most sensitive xenograft line,
a xenograft line with a mutation in EGFR, tumor uptake
of
11C-erlotinib was the highest, indicating that
11C-erlo-
tinib PET can indeed identify erlotinib sensitive tumors
(Fig. 3).
Conclusion
mAbs and TKIs are forming the most rapidly expanding
categories of targeted therapies; however, the efficacy of
these drugs is still quite limited, with benefit for just a
portion of patients. Immuno-PET and TKI-PET are attrac-
tive for studying the in vivo behavior of therapeutic mAbs
and TKIs and their interaction with critical disease targets
because it enables quantitative imaging of these drugs at
high resolution and sensitivity. Review of the literature
shows that immuno-PET and TKI-PET might form an
attractive tool to allow better understanding of targeted
therapy efficacy, more efficient drug development, and more
patient-tailored therapy.
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